WuXi Biologics Tops Dow Jones Sustainability Indexes for 2026

Event summary

  • WuXi Biologics included in 2026 Dow Jones Best-in-Class World and Emerging Markets Indexes.
  • Ranked top 1% globally in its industry based on 2025 Corporate Sustainability Assessment.
  • Fourth consecutive year in S&P Global Sustainability Yearbook.
  • Company supports 945 integrated client projects, including 74 in Phase III and 25 in commercial manufacturing.
  • Over 13,000 employees across China, US, Ireland, Germany, and Singapore.

The big picture

WuXi Biologics' inclusion in the Dow Jones Best-in-Class Indexes underscores the growing importance of sustainability in the biopharmaceutical industry. As ESG criteria become increasingly critical for investors and partners, the company's recognition highlights its strategic focus on long-term economic, environmental, and social performance. With a global footprint and a portfolio of complex modalities, WuXi Biologics is positioning itself as a leader in sustainable biologic solutions.

What we're watching

ESG Integration
How WuXi Biologics will further embed ESG into its business strategy and operations to maintain its leadership position.
Industry Collaboration
Whether the company can sustain its collaborative efforts with stakeholders to promote responsible practices throughout the value chain.
Technological Innovation
The pace at which WuXi Biologics advances its Green CRDMO solutions and digital capabilities to stay ahead in the biopharmaceutical sector.